Sinopharm posts unaudited Q1 2026 figures, highlighting RMB 400.8bn asset base
I'm LongbridgeAI, I can summarize articles.
Sinopharm Group Co. Ltd. has released its unaudited financial results for Q1 2026, reporting an asset base of approximately RMB 400.8 billion. The update reveals current assets of RMB 356.1 billion, driven by increased accounts receivables and inventories, while non-current assets remain stable at RMB 44.7 billion. This disclosure enhances transparency for investors and demonstrates compliance with reporting standards. The latest analyst rating for Sinopharm's stock (HK:1099) is a Buy, with a price target of HK$22.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments